Evolution of fibrosis during HCV recurrence after liver transplantation - influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
- 23 April 2013
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 20 (11) , 770-778
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantationJournal of Viral Hepatitis, 2012
- Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirinJournal of Hepatology, 2008
- High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantationScandinavian Journal of Infectious Diseases, 2008
- Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinomaJournal of Hepatology, 2007
- Liver Transplantation for HCV Cirrhosis at Karolinska University Hospital Huddinge, StockholmTransplantation Proceedings, 2006
- Treating hepatitis C infection in liver transplant recipientsLiver Transplantation, 2006
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- The association between hepatitis C infection and survival after orthotopic liver transplantationGastroenterology, 2002
- Long-Term Outcome of Hepatitis C Infection after Liver TransplantationNew England Journal of Medicine, 1996